Get the Stockscreener App
11.47
0.97%
0.11
After Hours:
11.42
-0.05
-0.44%
Evommune Inc stock is traded at $11.47, with a volume of 300.95K.
It is up +0.97% in the last 24 hours and down -54.45% over the past month.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
See More
Previous Close:
$11.36
Open:
$11.45
24h Volume:
300.95K
Relative Volume:
0.41
Market Cap:
$413.13M
Revenue:
$10.00M
Net Income/Loss:
$-75.99M
P/E Ratio:
-4.8046
EPS:
-2.3873
Net Cash Flow:
$-80.36M
1W Performance:
-0.52%
1M Performance:
-54.45%
6M Performance:
-41.48%
1Y Performance:
+0.00%
1-Day Range:
$11.21
$12.01
1-Week Range:
$10.47
$12.37
52-Week Range:
$10.47
$33.20
Evommune Inc Stock (EVMN) Company Profile
Name
Evommune Inc
Sector
Industry
Phone
(650) 223-7745
Address
1891 PAGE MILL RD, PALO ALTO
Compare EVMN vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVMN
Evommune Inc
|
11.47 | 409.17M | 10.00M | -75.99M | -80.36M | -2.3873 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Evommune Inc Stock (EVMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-26 | Resumed | Oppenheimer | Outperform |
| Jan-22-26 | Initiated | Oppenheimer | Outperform |
| Jan-08-26 | Initiated | Raymond James | Strong Buy |
| Jan-06-26 | Initiated | H.C. Wainwright | Buy |
| Dec-01-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-01-25 | Initiated | Evercore ISI | Outperform |
| Dec-01-25 | Initiated | Leerink Partners | Outperform |
| Dec-01-25 | Initiated | Morgan Stanley | Overweight |
| Dec-01-25 | Initiated | William Blair | Outperform |
View All
Evommune Inc Stock (EVMN) Latest News
Evommune, Inc. $EVMN Stake Lessened by Octagon Capital Advisors LP - MarketBeat
Evommune Inc (EVMN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
EVMN|Evommune Inc|Price:11.360|Chg%:+0.060 - TradingKey
Evommune Inc (EVMN) Cash Flow - TradingKey
TradingKey - TradingKey
Evommune Inc (EVMN) Balance Sheet - TradingKey
Evommune Inc (EVMN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Evommune Inc (EVMN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Evommune (EVMN) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
Top Evommune (EVMN) Competitors 2026 - MarketBeat
Long term debt to total assets ratio of Evommune, Inc. – BX:EVMNUSD - TradingView
Evommune Inc. Q1 2026 Earnings: EPS Beat Exceeds Expectations Amid Pre-Revenue PhaseSurprise Factor Analysis - dars.gov.et
This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism? - Stocktwits
Clear Street Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Evommune, Inc. (NYSE:EVMN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
If You Invested $1,000 in EVOMMUNE INC (EVMN) - Stock Titan
Kyle Carver Increases Stake in Evommune Inc with Recent Share Pu - GuruFocus
Evommune (NYSE:EVMN) CFO Acquires 1,000 Shares of Stock - MarketBeat
Independent Director of Evommune Arthur Kirsch Buys More Stock - simplywall.st
Form 4 Evommune Inc For: 8 July By Investing.com - Investing.com South Africa
Evommune director Arthur Kirsch buys $133,000 of EVMN stock By Investing.com - Investing.com India
Evommune (NYSE:EVMN) Director Acquires $133,000.00 in Stock - MarketBeat
Evommune director Arthur Kirsch buys $133,000 of EVMN stock - Investing.com
Evommune, Inc. (EVMN) Securities Fraud InvestigationLevi & Korsinsky - PR Newswire
Evommune Inc. (EVMN) Rises 3.4%: Testing Key Resistance LevelsSymmetrical Triangle - dars.gov.et
Stifel Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $54 - Moomoo
Top 3 Health Care Stocks That May Rocket Higher In July - Benzinga
EVMNEvommune Inc Options - Finviz
Evommune, Inc. (NYSE: EVMN) Stock Price, News & Analysis - Kalkine
Evommune’s EVO756 Trial Completion Signals Key Milestone in Chronic Urticaria Market - TipRanks
Evommune’s Healthy Balance Sheet Buys Them Time For AD (NYSE:EVMN) - Seeking Alpha
Evommune drops on phase 2 data for EVO756 in urticaria - MSN
Evommune's EVO756 trial miss raises doubts but pipeline and finances remain strong. - Pluang
Oral CSU Drug Falls Short in Phase 2b Study; Evommune Ends Development - The Dermatology Digest
Evommune shares plunge 38% after lead drug fails Phase 2b trial; insiders sold shares days before news. - Pluang
Evommune, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Evommune, Inc. (EVMN) - Morningstar
EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal - The Globe and Mail
Evommune stock downgraded by H.C. Wainwright after trial failure - Investing.com South Africa
EVMN Maintained by Morgan Stanley -- Price Target Lowered to $26 - GuruFocus
Morgan Stanley Maintains Evommune(EVMN.US) With Buy Rating, Cuts Target Price to $26 - Moomoo
Evommune Inc : RBC Cuts Target Price to $30 F - Moomoo
A Quick Look at Today's Ratings for Evommune(EVMN.US), With a Forecast Between $26 to $28 - Moomoo
This AAR Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday - Benzinga
Evommune ends development of lead asset in chronic hives after mid-stage efficacy woes - BioSpace
EVMN Downgraded by HC Wainwright & Co. -- Rating Changed to Neut - GuruFocus
Evommune Inc Stock (EVMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):